EMA Suspended: Oxbryta (voxelotor) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA suspended Oxbryta (voxelotor) for treating sickle cell disease-related anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Hemolytic Anemia
• Sickle Cell Disease

Drugs mentioned

• Oxbryta (voxelotor)

Snippet

Status: Suspended. Therapeutic area: Anemia;Anemia, Hemolytic;Anemia, Sickle Cell. MAH: Pfizer Europe MA EEIG. Decision date: 17/05/2024. Orphan medicine